Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.
about
Impact of CYP2C9 polymorphisms on the vulnerability to pharmacokinetic drug-drug interactions during acenocoumarol treatment.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Impact of CYP2C9 polymorphisms ...... uring acenocoumarol treatment.
@en
Impact of CYP2C9 polymorphisms ...... uring acenocoumarol treatment.
@nl
type
label
Impact of CYP2C9 polymorphisms ...... uring acenocoumarol treatment.
@en
Impact of CYP2C9 polymorphisms ...... uring acenocoumarol treatment.
@nl
prefLabel
Impact of CYP2C9 polymorphisms ...... uring acenocoumarol treatment.
@en
Impact of CYP2C9 polymorphisms ...... uring acenocoumarol treatment.
@nl
P2093
P2860
P356
P1433
P1476
Impact of CYP2C9 polymorphisms ...... uring acenocoumarol treatment.
@en
P2093
Alain Matthey
Christophe Combescure
Françoise Boehlen
Jules Alexandre Desmeules
Liliane Gschwind
Michela Rebsamen
Michèle Grünenwald
Pascal Bonnabry
Pierre Dayer
Victoria Rollason
P2860
P304
P356
10.2217/PGS.13.55
P577
2013-05-01T00:00:00Z